Active Implants Appoints Charles W. Federico and Gary D. Henley to Board

MEMPHIS, Tenn.–(BUSINESS WIRE)–Active Implants, a company that develops orthopedic implant solutions, today announced the appointments of orthopedic and sports medicine industry veterans Charles W. Federico and Gary D. Henley to its board of managers.

“Both Charlie and Gary are respected leaders with long-term success in medical and orthopedic device industries, and they bring a wealth of strategic and operational experience to our board,” said Ted Davis, president and chief executive officer of Active Implants. “We believe their diverse leadership experience will strengthen our board, and their insights will be invaluable as we continue to develop the NUsurface Meniscus Implant and fulfill a significant unmet need in the orthopedic market here in the U.S. and worldwide.”

Federico has 44 years of experience in the medical device industry, with significant focus in the sports medicine segment while president and chief executive officer of Orthofix International N.V. and president of Smith & Nephew Endoscopy. Additionally, he has held senior management and sales and marketing positions with Dyonics, General Foods Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Federico has extensive board experience, including chairman of the board and lead director of MAKO Surgical Corp, sold to Stryker; and a board member at Biomimetic Therapeutics, sold to Wright Medical Group.

Henley has more than 35 years of experience in the orthopedic device industry, including president, chief executive officer and board member of United Orthopedic Group, which was sold to Breg. Previously, he was president and chief executive officer of Wright Medical Group, Inc.; president of Orthofix International N.V.’s Americas Division; president of Smith & Nephew’s Endoscopy Video Division; and president and chief executive officer of Cecorp, Inc. Henley is an experienced board member and industry consultant, most recently serving as executive chairman of the board of directors at OrthAlign, Inc. and a director at Orchid Orthopedic Solutions.

With the appointment of Federico and Henley, Active Implants’ board consists of eight members: Henry Klyce, chairman of the board; Ted Davis, Active Implants CEO; James D. Lackie; William T. Mays, Jr.; Haynes Morris; and Spence Wilson, Jr.

About the NUsurface® Meniscus Implant

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade polymer and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. The NUsurface Meniscus Implant has been used in Europe under CE Mark since 2008 and in Israel since 2011. Clinical trials are underway in the U.S., Europe and Israel to verify the safety and effectiveness of the NUsurface Meniscus Implant.

About Active Implants LLC

Active Implants LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Haarlem, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.